With rich international experience of its management team and strategic geographic location in China’s Medicine Valley in Shanghai, Zerun has demonstrated the industry leading partnership and business development capability. In 2015, Zerun was awarded a $5 million research grant from the Bill & Melinda Gates Foundation to accelerate its bivalent HPV vaccine development and WHO prequalification process. Anchored on this significant achievement, Zerun kick-started its international expansion with its initial goal to provide affordable HPV vaccine to women and girls living in developing countries. As a result, Zerun cements its close collaborations with global institutions and charitable organizations including WHO, UNICEF, PATH, GAVI, DCVMN and CEPI.Zerun continues seeking collaboration opportunities with partners and offers its vaccine development expertise to bring more innovative products to the vast Chinese market and help partners to maximize the return of their investments in product and technology development.

Joint efforts to protect human health

Zerun hopes to explore cooperation with potential partners in the following areas.

For more information, please contact Zerun at zerunbd@walvax.com

  • Co-develop novel vaccines for neglected and emerging infectious diseases including preclinical development, clinical development and commercialization;

  • Provide value-added CRO services to partners from preclinical development, clinical development, and process development, to clinical study supplies manufacturing and testing. 

  • License in or license out of mature vaccine products or innovative technology platforms to expedite commercialization and product launch in domestic and global markets;

  • Explore equity investment to partner companies for their vaccine projects;